Follow
David W. Cescon
David W. Cescon
Medical Oncologist and Clinician Scientist, Princess Margaret Cancer Centre, University of Toronto
Verified email at uhn.ca
Title
Cited by
Cited by
Year
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth, LM Matukas, GA Tomlinson, AR Rachlis, DB Rose, HA Dwosh, ...
Jama 289 (21), 2801-2809, 2003
18762003
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 …
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
The Lancet 396 (10265), 1817-1828, 2020
11882020
Functional variants of OCTN cation transporter genes are associated with Crohn disease
VD Peltekova, RF Wintle, LA Rubin, CI Amos, Q Huang, X Gu, B Newman, ...
Nature genetics 36 (5), 471-475, 2004
9812004
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression
IS Harris, AE Treloar, S Inoue, M Sasaki, C Gorrini, KC Lee, KY Yung, ...
Cancer cell 27 (2), 211-222, 2015
9022015
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Annals of Oncology 30 (3), 397-404, 2019
6832019
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ...
Annals of Oncology 30 (3), 405-411, 2019
5302019
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
H Xu, M Di Antonio, S McKinney, V Mathew, B Ho, NJ O’Neil, ND Santos, ...
Nature communications 8 (1), 14432, 2017
4652017
Circulating tumor DNA and liquid biopsy in oncology
DW Cescon, SV Bratman, SM Chan, LL Siu
Nature Cancer 1 (3), 276-290, 2020
3632020
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ...
New England Journal of Medicine 387 (3), 217-226, 2022
3392022
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
C Gorrini, PS Baniasadi, IS Harris, J Silvester, S Inoue, B Snow, PA Joshi, ...
Journal of Experimental Medicine 210 (8), 1529-1544, 2013
3002013
Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2
S Inoue, WY Li, A Tseng, I Beerman, AJ Elia, SC Bendall, F Lemonnier, ...
Cancer cell 30 (2), 337-348, 2016
2052016
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or …
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
Journal of Clinical Oncology 38 (15_suppl), 1000-1000, 2020
1962020
Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086
S Loi, S Adams, P Schmid, J Cortés, DW Cescon, EP Winer, ...
Annals of Oncology 28, v608, 2017
1892017
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent
JM Mason, DCC Lin, X Wei, Y Che, Y Yao, R Kiarash, DW Cescon, ...
Cancer cell 26 (2), 163-176, 2014
1802014
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Journal of Clinical Oncology 35 (15_suppl), 1008-1008, 2017
1692017
Evolution of the randomized controlled trial in oncology over three decades
CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska
Journal of Clinical Oncology 26 (33), 5458, 2008
1652008
If we build it they will come: targeting the immune response to breast cancer
ME Gatti-Mays, JM Balko, SR Gameiro, HD Bear, S Prabhakaran, J Fukui, ...
NPJ breast cancer 5 (1), 37, 2019
1642019
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis
H Goldvaser, TA Barnes, B Šeruga, DW Cescon, A Ocaña, D Ribnikar, ...
JNCI: Journal of the National Cancer Institute 110 (1), 31-39, 2018
1632018
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Q Wu, W Ba-Alawi, G Deblois, J Cruickshank, S Duan, E Lima-Fernandes, ...
Nature communications 11 (1), 4205, 2020
1622020
A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease
B Newman, X Gu, R Wintle, D Cescon, M Yazdanpanah, X Liu, ...
Gastroenterology 128 (2), 260-269, 2005
1562005
The system can't perform the operation now. Try again later.
Articles 1–20